查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2135436

異檸檬酸去氫酶抑制劑市場：全球市場預測，2026-2032年

Isocitrate Dehydrogenase Inhibitors Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，異檸檬酸去氫酶抑制劑市場規模將達到 50.9 億美元，複合年成長率為 13.24%。

主要市場統計數據
基準年 2025 21.3億美元
預計年份：2026年 23.6億美元
預測年份 2032 50.9億美元
複合年成長率 (%) 13.24%

異檸檬酸去氫酶抑制劑是標靶治療，旨在抑制由特定突變引起的IDH1或IDH2酶活性異常。它們在某些骨髓惡性腫瘤中的臨床效用已得到證實，並且在其他腫瘤領域也正在進行評估。此市場的發展受到以下因素的影響：基於生物標記的診斷需求、針對特定突變的治療選擇、監管證據要求、伴隨診斷以及在不斷發展的治療路徑中對治療方案的定位。

精準腫瘤學正在重新思考IDH抑制劑的使用。

治療趨勢正從廣譜細胞毒性療法轉向分子標靶療法。 IDH突變檢測對患者的入組合格、治療順序和臨床試驗入組的影響日益顯著，但在實際臨床實踐中，仍需關注抗藥性、復發、耐受性、藥物交互作用以及新診斷病例和復發病例之間的差異。此外，分子標靶療法的推廣應用還取決於多種因素的整合，例如口服藥物的廣泛可及性、專科醫生的處方權、診斷的可及性、醫保報銷政策以及臨床指南的更新。

人工智慧可以增強生物標記和治療決策。

人工智慧可以透過改善基因組和臨床數據的解讀、識別可能從IDH標靶治療中獲益的患者以及協助研究人員確定藥物組合和抗藥性機制的優先級，為該領域提供支援。機器學習工具在影像分析、安全性監測、臨床試驗招募和縱向結果評估方面也發揮著重要作用。其價值取決於檢驗的資料集、透明的效能評估、適當的臨床監督、病患資料的保護，以及確保演算法輸出能夠增強而非取代專家判斷。

六個醫療保健環境的區域洞察

北美受益於先進的腫瘤中心、成熟的分子診斷技術和活躍的臨床研究，但保險報銷和治療機會方面的差異仍然是需要重點考慮的問題。歐洲擁有強大的學術基礎設施，但在醫療技術評估、診斷路徑和資金籌措也存在國家間的差異。亞太地區的精準腫瘤學能力正在不斷提升，但在定序、專家知識和創新藥物的可及性方面仍存在差異。拉丁美洲受到診斷基礎設施、公共部門採購和經濟限制的限制。在中東，專業的癌症照護服務和基因組分析能力正在發展，但不同醫療體系的可近性卻存在差異。非洲在病理學、分子檢測和腫瘤學方面的人力資源以及治療資源的可近性方面存在顯著差異，因此加強診斷系統對於取得進展至關重要。

群體特定分析揭示了不同的政策和准入優先事項。

東南亞國協腫瘤學現代化進程不一，導致分子偵測能力及健保報銷體係有顯著差異。金磚國家擁有卓越的研發和生產能力，但不同地區和收入水平的民眾獲得醫療服務的途徑存在差異。歐盟受益於科學和監管合作，但成員國在評估和資金籌措方面仍存在差距。七國集團（G7）國家普遍擁有成熟的腫瘤學基礎設施，但財政負擔能力和公平取得醫療服務仍是政策關注的重點。海灣合作理事會（GCC）國家正加大專科醫學和基因組醫學的投資，並輔以協調的採購和人力資源發展。北約成員國的醫療保健體系各不相同，因此共用研究能力並不能消除診斷、醫保報銷或臨床應用上的差異。

各國具體情況會影響診斷和治療的整合。

美國和加拿大擁有強大的專科網路和分子腫瘤學能力，但醫療服務的可近性受保險公司政策和州/省級體系的影響。德國、法國、義大利、西班牙和英國擁有先進的癌症治療服務，並結合各自獨特的監管、評估和報銷流程。澳洲擁有先進的臨床研究和集中式公共衛生體系，但地域差異仍然是醫療服務可近性面臨的重大挑戰。日本和韓國已建立起高品質的腫瘤學和診斷基礎設施，但國家批准和保險覆蓋流程影響醫療服務的利用。中國正在擴大精準醫療和國內研究能力，同時也努力解決區域差異問題。在印度，都市區癌症治療服務可近性有顯著差異。巴西和墨西哥正在加強癌症治療服務，但在診斷和資金籌措仍存在差距。俄羅斯擁有豐富的科學專業知識，但醫療服務的可近性和提供方式因地區而異。在所有國家，可靠的基因突變檢測和協調的多學科診療都是基礎。

精準腫瘤學領導者的優先事項

產業領導者應根據​​明確定義的IDH突變、具有臨床意義的終點以及反映常規實踐的證據，推動臨床開發，以服務特定患者群體。診斷領域的夥伴關係應支持準確、快速且經濟的突變檢測，而非將檢測視為次要活動。各機構必須透過轉化研究和合理的聯合用藥策略來解決抗藥性問題，同時維持嚴格的安全監測和交互作用管理。准入計劃必須涵蓋報銷理由、專科醫生教育、患者支持以及區域診斷差異。負責任地使用人工智慧（AI）需要前瞻性檢驗、管治、網路安全、偏差監測和人為課責。臨床醫生、實驗室、監管機構和患者團體之間的跨部門合作可以提高實施效果和證據品質。

調查方法執行摘要

本概要採用所提供的市場定義（異檸檬酸去氫酶抑制劑），並整合了關於IDH1和IDH2生物學、生物標記檢測、癌症治療、監管和可近性的既定科學和臨床原則。區域、群體和國家的具體觀察結果均為定性分析，基於公認的醫療基礎設施、診斷能力、研究活動和政策環境方面的差異。本概要不包含市場估算、預測、市場佔有率、展望或公司特定聲明。如需解讀本概要，請參閱最新的臨床指南、監管文件、同行評審的證據以及當地的保險報銷要求。

結論：生物標記的準確性和可及性將決定進展。

異檸檬酸去氫酶抑制劑的未來並非僅取決於酵素抑製作用的證實。要實現永續的臨床價值，需要精準的突變識別、合理的治療順序、抗藥性和毒性管理、可靠的診斷方法，以及公平地整合到癌症醫療體系中。由於區域和國家間的差異，部署策略至關重要，但人工智慧只有在檢驗和負責任的管理後才能發揮輔助作用。那些能夠將治療證據與診斷、患者就醫途徑和真實世界臨床結果相結合的領導者，將最有能力推進IDH標靶藥物的發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：異檸檬酸去氫酶抑制劑市場：按類型分類

  • 突變型Idh1抑制劑
  • 突變型Idh2抑制劑
  • 泛IDH抑制劑

第8章：異檸檬酸去氫酶抑制劑市場：依適應症分類

  • 急性骨髓性白血病
  • 膽管癌
  • 膠質瘤

第9章：異檸檬酸去氫酶抑制劑市場：依給藥途徑分類

  • 靜脈
  • 口服

第10章：異檸檬酸去氫酶抑制劑市場：依通路分類

  • 醫院藥房
  • 線上管道
  • 零售藥房

第11章：異檸檬酸去氫酶抑制劑市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院

第12章：異檸檬酸去氫酶抑制劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：異檸檬酸去氫酶抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：異檸檬酸去氫酶抑制劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Agios Pharmaceuticals, Inc.
  • Aslan Pharmaceuticals
  • Bayer Aktiengesellschaft
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • CStone Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Forma Therapeutics, Inc.
  • HUTCHMED Limited
  • Kura Oncology, Inc.
  • Les Laboratoires Servier
  • Merck & Co., Inc.
  • Novartis AG
  • Ohm Oncology
  • Pfizer, Inc.
  • Philogen SpA
  • Rigel Pharmaceuticals, Inc.
  • Roche Holding AG
  • Taiho Pharmaceutical Co., Ltd.
  • Tragara BioSciences, Inc.

第17章 主要專家

Product Code: MRR-961F26FD643B

The Isocitrate Dehydrogenase Inhibitors Market is projected to grow by USD 5.09 billion at a CAGR of 13.24% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.13 billion
Estimated Year [2026] USD 2.36 billion
Forecast Year [2032] USD 5.09 billion
CAGR (%) 13.24%

Isocitrate dehydrogenase inhibitors are targeted medicines designed to suppress abnormal IDH1 or IDH2 enzyme activity caused by specific mutations. Their clinical relevance is established in selected hematologic malignancies and is being evaluated in additional tumor settings. The market is shaped by biomarker-based diagnosis, mutation-specific treatment selection, regulatory evidence requirements, companion diagnostics, and the need to position therapy within evolving care pathways.

Precision Oncology Is Reshaping IDH Inhibitor Use

The landscape is shifting from broad cytotoxic treatment toward molecularly defined care. IDH mutation testing increasingly influences eligibility, treatment sequencing, and clinical-trial enrollment, while real-world practice must address resistance, relapse, tolerability, drug interactions, and differences between newly diagnosed and relapsed disease. Adoption also depends on the integration of oral treatment, specialist prescribing, diagnostic access, reimbursement rules, and clinical guideline updates.

Artificial Intelligence Strengthens Biomarker and Treatment Decisions

Artificial intelligence can support this field by improving interpretation of genomic and clinical data, identifying patients likely to benefit from IDH-directed therapy, and helping researchers prioritize combinations and resistance mechanisms. Machine-learning tools may also assist image analysis, safety monitoring, trial recruitment, and longitudinal outcome assessment. Their value depends on validated datasets, transparent performance, appropriate clinical oversight, protection of patient data, and confirmation that algorithmic outputs improve rather than replace expert judgment.

Regional Insights Across Six Healthcare Landscapes

North America benefits from advanced oncology centers, established molecular diagnostics, and active clinical research, although reimbursement variation and treatment access remain important considerations. Europe combines strong academic infrastructure with country-level differences in health-technology assessment, diagnostic pathways, and funding. Asia-Pacific presents expanding precision-oncology capacity alongside uneven access to sequencing, specialist expertise, and innovative medicines. Latin America is influenced by diagnostic infrastructure, public-sector procurement, and affordability constraints. The Middle East is developing specialized cancer services and genomic capabilities, with access varying across health systems. Africa faces substantial disparities in pathology, molecular testing, oncology workforce capacity, and treatment availability, making diagnostic strengthening central to progress.

Group Insights Reveal Different Policy and Access Priorities

ASEAN countries are pursuing oncology modernization at different speeds, with molecular testing capacity and reimbursement creating meaningful variation. BRICS economies combine significant research and manufacturing capabilities with uneven access across regions and income groups. The European Union benefits from collaborative scientific and regulatory structures but retains national differences in assessment and financing. G7 members generally possess mature oncology infrastructure, while affordability and equitable access remain policy concerns. GCC states are investing in specialized care and genomic medicine, with coordinated procurement and workforce development supporting implementation. NATO members span diverse health systems, so shared research capacity does not eliminate differences in diagnosis, reimbursement, or clinical uptake.

Country-Level Conditions Affect Diagnosis and Treatment Integration

The United States and Canada have strong specialist networks and molecular oncology capabilities, with access shaped by payer policy and provincial or state-level systems. Germany, France, Italy, Spain, and the United Kingdom combine sophisticated cancer services with distinct regulatory, assessment, and reimbursement processes. Australia has advanced clinical research and centralized public-health structures, but geographic access remains relevant. Japan and South Korea support high-quality oncology and diagnostic infrastructure, with national approval and coverage pathways influencing use. China is expanding precision medicine and domestic research capacity while navigating regional variation. India faces major differences between metropolitan and rural oncology access. Brazil and Mexico are strengthening cancer services but continue to encounter diagnostic and financing disparities. Russia has substantial scientific expertise, while access and care delivery may vary by region. Across all countries, reliable mutation testing and coordinated multidisciplinary care are foundational.

Priorities for Leaders in Precision Oncology

Industry leaders should align clinical development with clearly defined IDH-mutated populations, clinically meaningful endpoints, and evidence that reflects routine practice. Diagnostic partnerships should support accurate, timely, and affordable mutation testing rather than treating testing as a secondary activity. Organizations should prepare for resistance through translational research and rational combination strategies, while maintaining rigorous safety surveillance and interaction management. Access planning should address reimbursement evidence, specialist education, patient support, and regional diagnostic gaps. Responsible use of artificial intelligence requires prospective validation, governance, cybersecurity, bias monitoring, and human accountability. Cross-sector collaboration among clinicians, laboratories, regulators, and patient groups can improve implementation and evidence quality.

Research Methodology for the Executive Summary

This summary uses the supplied market definition-Isocitrate Dehydrogenase Inhibitors-and synthesizes established scientific and clinical principles concerning IDH1 and IDH2 biology, biomarker testing, oncology care delivery, regulation, and access. Regional, group, and country observations are qualitative and based on publicly recognized differences in healthcare infrastructure, diagnostic capacity, research activity, and policy environments. No market estimates, market shares, forecasts, or company-specific claims are included. Interpretation should be complemented by current clinical guidelines, regulatory documents, peer-reviewed evidence, and local reimbursement requirements.

Conclusion: Biomarker Precision and Access Will Define Progress

The future of isocitrate dehydrogenase inhibitors depends on more than demonstrating enzyme inhibition. Durable clinical value will require accurate mutation identification, appropriate treatment sequencing, management of resistance and toxicity, dependable diagnostics, and equitable integration into oncology systems. Regional and national differences make implementation strategies essential, while artificial intelligence offers supportive capabilities only when validated and governed responsibly. Leaders that connect therapeutic evidence with diagnostics, patient access, and real-world outcomes will be best positioned to advance IDH-directed care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Isocitrate Dehydrogenase Inhibitors Market, by Type

  • 7.1. Introduction
  • 7.2. Mutant Idh1 Inhibitors
  • 7.3. Mutant Idh2 Inhibitors
  • 7.4. Pan-Idh Inhibitors

8. Isocitrate Dehydrogenase Inhibitors Market, by Indication

  • 8.1. Introduction
  • 8.2. Acute Myeloid Leukemia
  • 8.3. Cholangiocarcinoma
  • 8.4. Glioma

9. Isocitrate Dehydrogenase Inhibitors Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral

10. Isocitrate Dehydrogenase Inhibitors Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Channel
  • 10.4. Retail Pharmacy

11. Isocitrate Dehydrogenase Inhibitors Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Clinics
  • 11.4. Hospitals

12. Isocitrate Dehydrogenase Inhibitors Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Isocitrate Dehydrogenase Inhibitors Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Isocitrate Dehydrogenase Inhibitors Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Agios Pharmaceuticals, Inc.
  • 16.2. Aslan Pharmaceuticals
  • 16.3. Bayer Aktiengesellschaft
  • 16.4. Bristol-Myers Squibb Company
  • 16.5. Celgene Corporation
  • 16.6. CStone Pharmaceuticals
  • 16.7. Daiichi Sankyo Company, Limited
  • 16.8. Forma Therapeutics, Inc.
  • 16.9. HUTCHMED Limited
  • 16.10. Kura Oncology, Inc.
  • 16.11. Les Laboratoires Servier
  • 16.12. Merck & Co., Inc.
  • 16.13. Novartis AG
  • 16.14. Ohm Oncology
  • 16.15. Pfizer, Inc.
  • 16.16. Philogen S.p.A.
  • 16.17. Rigel Pharmaceuticals, Inc.
  • 16.18. Roche Holding AG
  • 16.19. Taiho Pharmaceutical Co., Ltd.
  • 16.20. Tragara BioSciences, Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Isocitrate Dehydrogenase Inhibitors Market, Years Considered for the Study
  • FIGURE 2. Global Isocitrate Dehydrogenase Inhibitors Market, Research Design
  • FIGURE 3. Global Isocitrate Dehydrogenase Inhibitors Market, Research Framework
  • FIGURE 4. Global Isocitrate Dehydrogenase Inhibitors Market, Data Triangulation
  • FIGURE 5. Global Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 9. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 11. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 13. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Isocitrate Dehydrogenase Inhibitors Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Isocitrate Dehydrogenase Inhibitors Market Segmentation & Coverage
  • TABLE 2. Global Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 4. Global Mutant Idh1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Mutant Idh1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Mutant Idh1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Mutant Idh2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Mutant Idh2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Mutant Idh2 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Pan-Idh Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Pan-Idh Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Pan-Idh Inhibitors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 14. Global Acute Myeloid Leukemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Acute Myeloid Leukemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Acute Myeloid Leukemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Cholangiocarcinoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Cholangiocarcinoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Cholangiocarcinoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Glioma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Glioma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Glioma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 24. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 31. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Online Channel Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Online Channel Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Online Channel Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 41. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 53. Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 54. Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 55. Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 56. Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 57. North America Isocitrate Dehydrogenase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. North America Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 59. North America Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 60. North America Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 61. North America Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 62. North America Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 63. Latin America Isocitrate Dehydrogenase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Latin America Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 65. Latin America Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 66. Latin America Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 67. Latin America Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 68. Latin America Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 69. Europe Isocitrate Dehydrogenase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Europe Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 71. Europe Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 72. Europe Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 73. Europe Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 74. Europe Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 75. Middle East Isocitrate Dehydrogenase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Middle East Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 77. Middle East Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 78. Middle East Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 79. Middle East Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 80. Middle East Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 81. Africa Isocitrate Dehydrogenase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Africa Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 83. Africa Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 84. Africa Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 85. Africa Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 86. Africa Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 87. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. ASEAN Isocitrate Dehydrogenase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 89. ASEAN Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 90. ASEAN Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 91. ASEAN Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 92. ASEAN Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 93. ASEAN Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 94. GCC Isocitrate Dehydrogenase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 95. GCC Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 96. GCC Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 97. GCC Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 98. GCC Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 99. GCC Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 100. European Union Isocitrate Dehydrogenase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 101. European Union Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 102. European Union Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 103. European Union Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 104. European Union Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 105. European Union Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 106. BRICS Isocitrate Dehydrogenase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 107. BRICS Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 108. BRICS Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 109. BRICS Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 110. BRICS Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 111. BRICS Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 112. G7 Isocitrate Dehydrogenase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 113. G7 Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 114. G7 Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 115. G7 Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 116. G7 Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 117. G7 Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 118. NATO Isocitrate Dehydrogenase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 119. NATO Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 120. NATO Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 121. NATO Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 122. NATO Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 123. NATO Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 124. Global Isocitrate Dehydrogenase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 125. United States Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 126. United States Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 127. United States Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 128. United States Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 129. United States Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 130. United States Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 131. Canada Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 132. Canada Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 133. Canada Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 134. Canada Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 135. Canada Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 136. Canada Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 137. Mexico Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 138. Mexico Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 139. Mexico Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 140. Mexico Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 141. Mexico Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 142. Mexico Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 143. Brazil Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 144. Brazil Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 145. Brazil Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 146. Brazil Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 147. Brazil Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 148. Brazil Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 149. United Kingdom Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 150. United Kingdom Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 151. United Kingdom Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 152. United Kingdom Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 153. United Kingdom Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 154. United Kingdom Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 155. Germany Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 156. Germany Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 157. Germany Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 158. Germany Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 159. Germany Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 160. Germany Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 161. France Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 162. France Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 163. France Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 164. France Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 165. France Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 166. France Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 167. Russia Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 168. Russia Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 169. Russia Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 170. Russia Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 171. Russia Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 172. Russia Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 173. Italy Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 174. Italy Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 175. Italy Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 176. Italy Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 177. Italy Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 178. Italy Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 179. Spain Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 180. Spain Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 181. Spain Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 182. Spain Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 183. Spain Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 184. Spain Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 185. China Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 186. China Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 187. China Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 188. China Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 189. China Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 190. China Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 191. India Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 192. India Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 193. India Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 194. India Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 195. India Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 196. India Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 197. Japan Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 198. Japan Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 199. Japan Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 200. Japan Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 201. Japan Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 202. Japan Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 203. Australia Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 204. Australia Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 205. Australia Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 206. Australia Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 207. Australia Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 208. Australia Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 209. South Korea Isocitrate Dehydrogenase Inhibitors Market Size, 2017-2032 (USD Million)
  • TABLE 210. South Korea Isocitrate Dehydrogenase Inhibitors Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 211. South Korea Isocitrate Dehydrogenase Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 212. South Korea Isocitrate Dehydrogenase Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 213. South Korea Isocitrate Dehydrogenase Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 214. South Korea Isocitrate Dehydrogenase Inhibitors Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 215. Global Isocitrate Dehydrogenase Inhibitors Market Share, by Key Player, 2025
  • TABLE 216. Global Isocitrate Dehydrogenase Inhibitors Market, Key Experts